Trial Profile
Pilot Study of Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
Status:
Recruiting
Phase of Trial:
Phase 0
Latest Information Update: 25 Oct 2023
Price :
$35
*
At a glance
- Drugs Binimetinib (Primary) ; Encorafenib (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 17 Oct 2023 Planned primary completion date changed from 1 May 2028 to 1 May 2024.
- 17 Oct 2023 Status changed from active, no longer recruiting to recruiting.
- 24 May 2023 Planned End Date changed from 1 Dec 2023 to 1 May 2028.